Stroke — An Equal Opportunity for the Initiation of Statin Therapy

Given the disparity in the numbers of cerebrovascular and cardiovascular clinical trials and the similarities in the interventions tested, it seems that stroke neurologists have had to peer at clinical-trial results over the shoulders of their cardiologist colleagues so often that they are at risk for chronic neck ailments. If only for evening the score a little, the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators deserve our gratitude.In their randomized clinical trial that was specifically designed to test statin therapy for the prevention of stroke recurrence in patients who had had a stroke or transient ischemic . . .